首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force
【24h】

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force

机译:临床结果评估:ISPOR 临床结果评估的概念基础报告 - 结果研究工作组的新兴良好实践

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

An outcome assessment, the patient assessment used in an endpoint, is the measuring instrument that provides a radng or score (categofical or continuous) that is intended to represent some aspect of the patient's health status. Outcome assessments are used to define efficacy endpoints when developing a therapy for a disease or condition. Most efficacy endpoints are based on specified clinical assessments of patients. When clinical assessments are used as clinical trial outcomes, they are called clinical outcome assessments (COAs). COAs include any assessment that may be influenced by human choices, judgment, or motivation. COAs must be well-defined and possess adequate measurement properties to demonstrate (directly or indirectly) the benefits of a treatment In contrast, a biomarker assessment is one that is subject to little, if any, patient motivational or rater judgmental influence. This is the first of two reports by the ISPOR Clinical Outcomes Assessment Emerging Good Practices for Outcomes Research Task Force. This report provides foundational definitions important for an understanding of COA measurement principles. The foundation provided in this report includes what it means to demonstrate a beneficial effect, how assessments of patients relate to the objective of showing a treatment's benefit, and how these assessments are used in clinical trial endpoints. In addition, this report describes intrinsic attributes of patient assessments and clinical trial factors that can affect the properties of the measurements. These factors should be considered when developing or refining assessments. These considerations will aid investigators designing trials in their choice of using an existing assessment or developing a new outcome assessment Although the focus of this report is on the development of a new COA to define endpoints in a clinical trial, these principles may be applied more generally. A critical element in appraising or developing a COA is to describe the treatment's intended benefit as an effect on a clearly identified aspect of how a patient feels or functions. l'his aspect must have importance to the patient and be part of the patient's typical life. this meaningful health aspect can be measured directly or measured indirectly when it is impractical to evaluate it directly or when it is difficult to measure. For indirect measurement, a concept of interest (COI) can be identified. The COI must be related to how a patient feels or functions. Procedures are then developed to measure the COI. The relationship of these measurements with how a patient feels or functions in the intended setting and manner of use of the COA (the context of use) could then be defined. A COA has identifiable attributes or characteristics that affect the measurement properties of the COA when used in endpoints. One of these features is whether judgment can influence the measurement, and if so, whose judgment. This attribute defines four categories of COAs: patient reported outcomes, clinician reported outcomes, observer reported outcomes, and performance outcomes. A full description as well as explanation of other important COA features is included in this report. The information in this report should aid in the development, refinement, and standardization of COAs, and, ultimately, improve their measurement propeities.
机译:结果评估,即终点中使用的患者评估,是提供旨在代表患者健康状况某些方面的 radng 或分数(分类或连续)的测量工具。结果评估用于在开发疾病或病症的疗法时确定疗效终点。大多数疗效终点基于对患者的特定临床评估。当临床评估用作临床试验结果时,它们被称为临床结果评估 (COA)。COA 包括任何可能受人类选择、判断或动机影响的评估。COA 必须定义明确并具有足够的测量特性,以证明(直接或间接)治疗的益处相比之下,生物标志物评估是一种几乎不受患者动机或评估者判断影响(如果有的话)的评估。这是 ISPOR 临床结果评估结果研究工作组新兴良好实践的两份报告中的第一份。本报告提供了对理解COA测量原理很重要的基本定义。本报告中提供的基础包括证明有益效果的含义,对患者的评估如何与显示治疗益处的目标相关,以及这些评估如何用于临床试验终点。此外,本报告还描述了患者评估的内在属性和可能影响测量特性的临床试验因素。在制定或完善评估时应考虑这些因素。这些考虑因素将有助于研究人员在设计试验时选择使用现有评估或开发新的结果评估 尽管本报告的重点是开发新的COA来定义临床试验中的终点,但这些原则可以更广泛地应用。评估或开发 COA 的一个关键要素是将治疗的预期益处描述为对患者感觉或功能的明确确定方面的影响。L'他的方面必须对患者很重要,并且是患者典型生活的一部分。这种有意义的健康方面可以直接测量,也可以在直接评估不切实际或难以测量时间接测量。对于间接测量,可以确定感兴趣的概念 (COI)。COI 必须与患者的感受或功能有关。然后制定程序来测量 COI。然后可以定义这些测量值与患者在 COA 的预期环境和使用方式(使用环境)中的感觉或功能的关系。COA 具有可识别的属性或特征,这些属性或特征在端点中使用时会影响 COA 的测量属性。其中一个特征是判断是否会影响测量,如果是,谁的判断。此属性定义了 COA 的四类:患者报告的结果、临床医生报告的结果、观察者报告的结果和表现结果。本报告包括对其他重要 COA 功能的完整描述和解释。本报告中的信息应有助于COA的开发、完善和标准化,并最终提高其测量能力。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号